Work

0737 Efficacy and Safety of Oveporexton (TAK-861), an Oral Orexin Receptor 2 Agonist, for Narcolepsy Type 1 Treatment: A Pooled Analysis of Phase 3 Studies

Year: 2026

Type: article

Source: SLEEP

DOI: 10.1093/sleep/zsag091.0736

Authors: Emmanuel Mignot, Yves Dauvilliers, Rafael Del Rio Villegas, Ramin Khatami, Gert Lammers, Alice Cai, Yeting Du, Mark Etherton, Samuel Hsiao, Harisha Kadali, Rachel Neuwirth, Tina Olsson, Christian Von Hehn, Baiyun Yao, Giuseppe Plazzi

Institutions: Stanford Medicine, Stanford University, Hôpital Gui de Chauliac, Klinik Barmelweid, Stichting Epilepsie Instellingen Nederland, Takeda (United States), Istituto delle Scienze Neurologiche di Bologna

Language: English

Topic: Sleep and Wakefulness Research

Subfield: Cognitive Neuroscience

Field: Neuroscience

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7160630392

FWCI: 4.212

Cites:

Cited by: 1

Related to: